Key result
Pre-stroke treatment with ACEI/ARB (n=119) was associated with worsened stroke severity and reduced early functional outcomes compared to non-users among 218 patients with ischemic stroke.
Why the study?
Although studies show pre-stroke ACEI/ARB use reduces severity and improves functional outcomes in ischemic stroke, the authors aimed to compare stroke severity and early functional outcomes between patients taking vs not taking ACEI/ARB, and assess additional effects with antiplatelets, statins, or both.
Does pre-stroke treatment with ACE inhibitors or Angiotensin Receptor Blockers improve stroke severity and early functional outcome in patients presenting with ischemic stroke?
Case-Control (n=218)
No
Does pre-stroke treatment with ACE inhibitors or Angiotensin Receptor Blockers improve stroke severity and early functional outcome in patients presenting with ischemic stroke?
In this retrospective study, pre-stroke use of ACEI/ARB was associated with worsened stroke severity and reduced early functional outcomes, contrasting with previous data suggesting a protective effect.
Answers are grounded in this paper and cite their sources.
Pre-stroke ACEI/ARB may worsen ischemic stroke outcomes; hypothesis-generating observational data that leaves practice implications open.
A growing number of clinical data suggests that the use of antiplatelets and/or statins pre-stroke are associated with reduced severity and better functional outcomes for ischemic stroke. Studies have shown that the long-term use of ACEI/ARB pre-stroke is beneficial in reducing severity at onset and improving functional outcomes. We aimed to compare stroke severity and early functional outcome between patients taking ACEI/ARB and those who were not, and to identify any additional effects to taking ACEI/ARB with antiplatelets, statins, or both. In this retrospective case-control study, we assessed 218 patients who presented with ischemic stroke to the stroke unit in Padeh-Poriyah Hospital between 2019-2020. Of these patients, 119 took ACEI/ARB pre-stroke. A significantly higher percentage of ACEI/ARB-treated patients had a history of hypertension (HTN) and hyperlipidemia and were taking antiplatelets and/or statins, compared to the non-ACEI/ARB group. We observed that pre-stroke treatment with ACEI/ARB is associated with worsened stroke severity and reduced early functional outcomes. No significant benefit to taking ACEI/ARB with antiplatelets and/or statins pre-stroke was observed. Due to the nature of our study, the data should be interpreted as suggestive. Thus, prospective studies of these medications on ischemic stroke severity and early outcomes are warranted.
No takes yet. Share an insight, caveat, or question.
Horrany et al. (2023) conducted a case-control in Ischemic stroke (n=218). ACE Inhibitors/Angiotensin Receptor Blockers (ACEI/ARB) vs. No pre-stroke ACEI/ARB use was evaluated on Stroke severity and early functional outcome. Pre-stroke treatment with ACEI/ARB (n=119) was associated with worsened stroke severity and reduced early functional outcomes compared to non-users among 218 patients with ischemic stroke.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: